Know Cancer

or
forgot password

Three Dimension Neuron Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Ventricular Tachycardia Ablations


N/A
18 Years
N/A
Open (Enrolling)
Both
Ventricular Tachycardia, Arrhythmia

Thank you

Trial Information

Three Dimension Neuron Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Ventricular Tachycardia Ablations


Ventricular tachycardia is the next frontier in cardiology. Patients that have scar in the
heart (for example after heart attacks) are at an increased risk of developing ventricular
tachycardia. In these patients ventricular tachycardia represents an electrical wave front
that circulates in the heart muscle using the scar in the heart. An increasing number of
patients with ventricular tachycardia require cauterization (burning away) of the tissue to
treat this life-threatening condition. The goal of this cauterization or ablation is to
destroy "highways of surviving tissue" inside the scar, that allow ventricular tachycardia
to exist. However, this can be very lengthy procedure (>5 hours) that has only a moderate
success in the long run. Therefore, new treatment approaches are needed to make this
procedure better.

The purpose of this study is to assess if radio tracers showing the nerve distribution in
the heart (cardiac innervation) can be used in addition to the current technology ("voltage
mapping") to identify the area that needs to be ablated (burnt away) to treat
life-threatening fast heart rates (ventricular tachycardia)

Certain patterns of nerve distribution in the heart (sympathetic cardiac innervation) have
been shown to predict outcome for different heart diseases, like heart transplant, coronary
artery disease, heart failure, arrhythmias. One substance that allows visualization of the
cardiac innervation is 123I-metaiodobenzylguanidine (123I-MIBG), which could provide
additional information to understand and treat ventricular tachycardia.


Inclusion Criteria:



- Patients with ventricular arrhythmias requiring VT Ablation

- Patients must be 18 years of age or older

- Patient must be able to sign consent form

- Patient must be willing to come back for the 6 month visit for additional study
procedures

Exclusion Criteria:

- Patient under 18 years old

- Inability to sign consent

- Pregnant Women

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Imaging of Nerve distribution in heart

Outcome Description:

Specific Aim 1: Evaluate if areas of left ventrical (LV) denervation measured by cardiac 123I-metaiodobenzylguanidine (MIBG) SPECT imaging (innervation map) can be integrated into the CartoXP electrophysiology mapping system. Participants will be followed for 6 months for an episode of Ventricular Tachycardia.

Outcome Time Frame:

6 months after procedure

Safety Issue:

No

Principal Investigator

Timm R Dickfeld, MD,Ph.D

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Maryland

Authority:

United States: Institutional Review Board

Study ID:

HP-00043324

NCT ID:

NCT01250912

Start Date:

March 2010

Completion Date:

December 2012

Related Keywords:

  • Ventricular Tachycardia
  • Arrhythmia
  • Ablation
  • Arrythmia
  • Imaging
  • Arrhythmias, Cardiac
  • Tachycardia
  • Tachycardia, Ventricular

Name

Location

University of Maryland Medical Center, EP Lab, Rm. N3W77Baltimore, Maryland  21201